Recruiting

Medication Adherence

Sponsor:

Duke University

Code:

NCT07811258

Conditions

Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Medisafe Medication Management Program

Pharmacist-Led Medication Review

Study Details

Brief summary:

This pilot study evaluates a pharmacist-led medication adherence intervention and Medisafe mobile application among patients with newly diagnosed cancer and multimorbidity. Thirty participants will be randomized to intervention or usual care to assess feasibility, acceptability, usability, and preliminary efficacy.

Conditions

Cancer

Study ID

NCT07811258

Start date

Nov 30, 2026

Status verified date

Aug, 2026

Completion date

Jun 30, 2027

Anticipated

Primary completion date

Jun 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • diagnosed with breast, colorectal, lung or prostate cancer in the previous 12 months
  • had no prior diagnosis of cancer
  • are currently undergoing chemotherapy or radiation and/or underwent surgery in the prior 3 months
  • had >2 chronic conditions for >1 year prior to cancer diagnosis
  • are prescribed >1 non-cancer medication(s)

Exclusion Criteria:

  • cannot read and communicate in English
  • do not have a smartphone

Study Design

Enrollment

30 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Intervention Arm

Pharmacist-led medication review plus Medisafe app support.

no intervention: Control Arm

Usual care.

Interventions

Medisafe Medication Management Program

Training and use of Medisafe application for medication adherence support.

Pharmacist-Led Medication Review

Comprehensive medication review and education by pharmacist.

Primary outcome measure

  • Feasibility, as measured by number of participants recruited [ Time Frame: 6 months ]
  • Feasibility, as measured by screening to enrollment ratio [ Time Frame: from screening to enrollment, approximately 2 weeks ]
  • Feasibility, as measured by completion rate of the comprehensive medication review [ Time Frame: from enrollment to completion of 6 month follow up ]
  • Feasibility, as measured by completion rate of the adherence log [ Time Frame: 3 months ]
  • Feasibility, as measured by completion rate of the adherence log [ Time Frame: 6 months ]
  • Acceptability, as measured by Acceptability of Intervention Measure [ Time Frame: 3 months, 6 months ]
  • Usability, as measured by the System Usability Score of the Medisafe application [ Time Frame: 3 months, 6 months ]
  • Patient-centeredness, as measured by the Patient-Centered Care Questionnaire [ Time Frame: 3 months ]
  • Patient-centeredness, as measured by the Patient-Centered Outcomes Questionnaire [ Time Frame: 3 months ]

Central Contacts and Locations

Locations

Duke University

Recruiting

Durham, North Carolina, United States, 27710

Contacts

Jhoanna Aquino

9196606189jhoannazaida.aquino@duke.edu

More Information

Sponsor

Duke University

Last update posted

Oct 30, 2026

Last verified

Aug, 2026

Keywords

  • Medication Adherence
  • Cancer Survivorship
  • Multimorbidity

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-31. This information was provided to ClinicalTrials.gov by Duke University on 2026-10-30. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.